Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone augmentation of exposure therapy for social anxiety disorder
NL-OMON20251Phase 3Active, not recruiting
- Sponsor
- Pro Persona
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Social Anxiety Disorder (SAD) comparing Exposure therapy plus testosterone with Exposure therapy plus placebo (2 arms). Primary endpoint: Reduction in social anxiety symptoms during exposure sessions. Started Sep 2017; status: active, not recruiting.
02
Drugs
testosterone
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NL-OMON20251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20251.